Tegaserod Post Marketing Issues Zelnorm, also known as tegaserod maleate, is a drug indicated for the treatment of irritable bowel syndrome (IBS). In 2002, the drug was initially approved for women with IBS whose predominant symptom was constipation. In 2004, the use of tegaserod was approved for men and women under 65 to treat chronic idiopathic constipation. Initial studies of the efficacy, safety, and tolerability of the drug demonstrated promising results. Tegaserod was shown to provide rapid, predictable, and consistent relief of chronic constipation.1 Additionally, only 1 percent of patients experienced significant adverse events but none of them were found to be attributable to the use of Tegaserod.1 In March 2007, the drug was pulled